



Press release |

IBA SELLS A CYCLONE® 30 TO INDIA

Embargo until 5:40 p.m. (Belgian time) – 26 February 2007

Louvain-la-Neuve, Belgium, 26 February 2007 – IBA (Ion Beam Applications S.A.: Reuters IOBAt.BR and Bloomberg IBAB.BB) today announces the finalising of a contract for the delivery of a Cyclone® 30 - a 30 MeV (Millions of Electron Volts) cyclotron - to the Indian Department of Atomic Energy (DAE). It will be used for the production of radioisotopes for medical purposes. The contract is worth an undisclosed figure somewhere between 5 and 10 million euros.

This cyclotron will be used to produce SPECT (single photon emission computed tomography) radioisotopes such as Thallium-201. It will also be fitted with a beam line for Research and Development purposes. It will mean that India will no longer have to depend on the costly importing of medical radioisotopes as the country will be able to produce them locally in order to serve a larger part of the Indian population. It will be set up on a new site at the VECC (Variable Energy Cyclotron Centre) belonging to the Indian Department of Atomic Energy (DAE) in Calcutta and is due to become operational in early 2009.

IBA's Cyclone® 30 is used by the world's major radioisotope producers. This proton accelerator is designed for both medical use and for research. It produces radioisotopes which are used both by hospitals' nuclear medicine departments and by medical imaging centres all over the world every day to carry out cutting edge clinical diagnosis in the fields of oncology, cardiology and neurology. IBA has 90% of the international market in this technology.

"After the sale of a Cyclone® 30 to Vietnam in early 2006 and an agreement subject to financing for a Cyclone® 30 in Turkey in mid-2006, we at IBA are once again proving our genuine leadership in the supplying of healthcare solutions based upon cyclotron technology", said Pierre Mottet, CEO of IBA. "The IBA mission statement is to provide the cutting edge tools required to combat cancer and this project further consolidates our position as the leader in this field."

Press release |

ABOUT IBA

IBA delivers solutions of a unique precision in the fields of **cancer diagnosis and therapy**. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Phone: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com

IBA's Cyclone® 30

